Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...

Novartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.

Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

In the corporate sector, Novartis (SIX: NOVN) stock rose 4% after Swiss drugmaker reported strong fourth-quarter results ...

Looking ahead to 2025, Novartis maintains an optimistic stance, forecasting mid to high single-digit sales growth and anticipating even stronger operational core earnings in the high single to low ...